Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

New research reveals how sleep apnea may accelerate brain aging and cognitive decline, with experts sharing crucial insights ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Sleep apnea is known to wreak havoc with the body, contributing to heart problems, diabetes and liver disease. The sleep disorder also appears to have direct effects on brain health, a new study ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

Share on Pinterest A new study links sleep apnea to changes in key brain regions related to memory. Image credit: Maskot/Getty Images. About 936 million adults around the world have sleep apnea.

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

THURSDAY, Dec. 19, 2024 (HealthDay News) -- Sleep apnea is known to wreak havoc with the body, contributing to heart problems, diabetes and liver disease. The sleep disorder also appears to have ...

including snoring and obstructive sleep apnea. Obstructive sleep apnea is when a person stops breathing five or more times per hour. When breathing stops, it can lower oxygen levels, affecting the ...